Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 1st Line

EGFR Wild-type; ALK-; RS01 -

LUN0092
Phase Ib PDR001 in Combination w/ Platinum-Doublt Chemotherapy in PD-1 Metastatic NSCLC
PI: Wakelee Novartis Pharmaceuticals

EGFR

LUN0102
Phase Ib/II G1T38 +/- Osimertinib in EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
PI: Padda Pending

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Link
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu